Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov;15(11):763-778.
doi: 10.2217/fvl-2020-0174. Epub 2020 Nov 30.

Nanoparticle vaccines against respiratory syncytial virus

Laura M Stephens  1 , Steven M Varga  1   2   3
Affiliations
Review

Nanoparticle vaccines against respiratory syncytial virus

Laura M Stephens et al. Future Virol. 2020 Nov.

Abstract

Respiratory syncytial virus (RSV) is a leading cause of respiratory disease in infants, the elderly and immunocompromised individuals. Despite the global burden, there is no licensed vaccine for RSV. Recent advances in the use of nanoparticle technology have provided new opportunities to address some of the limitations of conventional vaccines. Precise control over particle size and surface properties enhance antigen stability and prolong antigen release. Particle size can also be modified to target specific antigen-presenting cells in order to induce specific types of effector T-cell responses. Numerous nanoparticle-based vaccines are currently being evaluated for RSV including inorganic, polymeric and virus-like particle-based formulations. Here, we review the potential advantages of using different nanoparticle formulations in a vaccine for RSV, and discuss many examples of safe, and effective vaccines currently in both preclinical and clinical stages of testing.

Keywords: RSV; adjuvant; lung; nanoparticle; respiratory syncytial virus; vaccine.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure This work was supported by funds by the Iowa State University Nanovaccine Institute (to SM Varga) and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Numbers T32AI007485 (to LM Stephens) and R01AI124093 (to SM Varga). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

References

    1. Scheltema NM, Gentile A, Lucion F. et al. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series. Lancet Glob. Health 5(10), e984–e991 (2017). - PMC - PubMed
    1. Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 22(5), 275–284 (2004). - PubMed
    1. Nair H, Nokes DJ, Gessner BD. et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375(9725), 1545–1555 (2010). - PMC - PubMed
    1. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352(17), 1749–1759 (2005). - PubMed
    1. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163(4), 693–698 (1991). - PubMed

LinkOut - more resources